In STEP 1, 1,961 nondiabetic adults with overweight or obesity achieved an average 14.9% weight loss over 68 weeks when semaglutide was combined with lifestyle changes.20 STEP 2 examined 1210 individuals with T2DM and showed a more modest average weight loss of 9.6%, possibly due to insulin resistance and the influence of other diabetes medications.21 STEP 3 introduced a more intensive lifestyle intervention to participants who were overweight or obese but without T2DMincluding a calorie-restricted diet and behavioral supportand resulted in slightly higher weight loss amongst the 611 study participants, averaging around 16%.22 The STEP 4 trial included 811 individuals who were overweight or obese without diabetes and assessed the impact of discontinuing semaglutide after 20 weeks
Patients should keep a log of their symptoms, side effects, and any changes they notice
Reflux requires such aggressive medication management that the polypharmacy burden becomes problematic
Benefits of GLP-1s GLP-1s like Ozempic have cardiovascular and kidney benefits as well, explains King
However, several mechanistic hypotheses have emerged from preclinical work
It binds the growth hormone receptor (GHR), a class I cytokine receptor present as a preformed homodimer on target cells throughout the body
